Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

Veeva Systems (VEEV) beat estimates in Q2 fiscal 2027 and raised its full-year outlook, the headline fact behind a Zacks-flagged case for holding the stock rather than chasing it.

The growth engine is Vault CRM. Twelve of the top 20 biopharmas have committed to the platform, and more than 180 customers are already live. That adoption figure is the concrete proof point supporting the raised guidance. Separately, Veeva Falcon, part of the company's AI push, is attracting early adopters, though the article offers no revenue or customer figures for it.

The cautionary side is competitive. The life sciences CRM space is saturated, and competition is intensifying from both traditional and AI-powered platforms. Interpretation: with a dozen of the top 20 biopharmas already committed, the remaining pool of large, unconverted customers shrinks, which could pressure the pace of new-logo growth even as live deployments expand.

The Zacks framing, "hold for now," reflects that split: solid execution and a raised outlook weighed against a market with limited room to expand and more rivals entering. The stock's tickers in the same peer set, GMED, VCYT and WST, are not discussed in the source.